{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:22Z","timestamp":1792787302433,"version":"4.5.0"},"reference-count":76,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Cancer Prevention Research Institute of Texas for co-funding","award":["DP150029"],"award-info":[{"award-number":["DP150029"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,6,21]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale of the trial<\/jats:title>\n                    <jats:p>Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. We investigated the safety and tolerability of IMA202 in a first-in-human, dose escalation basket trial in human leucocyte antigen A*02:01 positive patients with melanoma-associated antigen A1 (MAGEA1)-positive advanced solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial design<\/jats:title>\n                    <jats:p>\n                      The 2+2 trial design was an algorithmic design based on a maximally acceptable dose-limiting toxicity (DLT) rate of 25% and the sample size was driven by the algorithmic design with a maximum of 16 patients. IMA202 consists of autologous genetically modified cytotoxic CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells expressing a T cell receptor (TCR), which is specific for a nine amino acid peptide derived from MAGEA1. Eligible patients underwent leukapheresis, T cells were isolated, transduced with lentiviral vector carrying MAGEA1-specific TCR and following lymphodepletion (fludarabine\/cyclophosphamide), infused with a median of 1.4\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      specific T cells (range, 0.086\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \u20132.57\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      ) followed by interleukin 2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Safety of IMA202<\/jats:title>\n                    <jats:p>No DLT was observed. The most common grade 3\u20134 adverse events were cytopenias, that is, neutropenia (81.3%), lymphopenia (75.0%), anemia (50.0%), thrombocytopenia (50.0%) and leukopenia (25.0%). 13 patients experienced cytokine release syndrome, including one grade 3 event. Immune effector cell-associated neurotoxicity syndrome was observed in two patients and was grade 1 in both.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Efficacy of IMA202<\/jats:title>\n                    <jats:p>Of the 16 patients dosed, 11 (68.8%) patients had stable disease (SD) as their best overall response (Response Evaluation Criteria in Solid Tumors V.1.1). Five patients had initial tumor shrinkage in target lesions and one patient with SD experienced continued shrinkage in target lesions for 3\u2009months in total but had to be classified as progressive disease due to progressive non-target lesions. IMA202 T cells were persistent in peripheral blood for several weeks to months and were also detectable in tumor tissue. Peak persistence was higher in patients who received higher doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, IMA202 had a manageable safety profile, and it was associated with biological and potential clinical activity of MAGEA1-targeting genetically engineered TCR-T cells in a poor prognosis, multi-indication solid tumor cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration numbers<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04639245\">NCT04639245<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05430555\">NCT05430555<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2023-008668","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T13:10:26Z","timestamp":1721653826000},"page":"e008668","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04639245","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05430555","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04639245","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05430555","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Martin","family":"Wermke","sequence":"first","affiliation":[{"name":"Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany"},{"name":"National Center for Tumor Diseases, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias A W","family":"Holderried","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-4908","authenticated-orcid":false,"given":"Jason John","family":"Luke","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van K","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center Division of Cancer Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried H","family":"Alsdorf","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology, and Bone Marrow Transplantation with Section Pneumology, University Hospital Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Wetzko","sequence":"additional","affiliation":[{"name":"Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borje S","family":"Andersson","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio I","family":"Wistuba","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin R","family":"Parra","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad B","family":"Hossain","sequence":"additional","affiliation":[{"name":"Immatics US, Inc, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Grund-Gr\u00f6schke","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Aslan","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Satelli","sequence":"additional","affiliation":[{"name":"Immatics US, Inc, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anantha","family":"Marisetty","sequence":"additional","affiliation":[{"name":"Immatics US, Inc, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna","family":"Satam","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Kalra","sequence":"additional","affiliation":[{"name":"Immatics US, Inc, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hukelmann","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Alper","family":"Kursunel","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Pozo","sequence":"additional","affiliation":[{"name":"Immatics US, Inc, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3391-2539","authenticated-orcid":false,"given":"Andreas","family":"Acs","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"Backert","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Baumeister","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bunk","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wagner","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schoor","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali S","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Immatics US, Inc, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mayer-Mokler","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Hilf","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delfi","family":"Krishna","sequence":"additional","affiliation":[{"name":"Immatics US, Inc, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Walter","sequence":"additional","affiliation":[{"name":"Immatics US, Inc, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-233X","authenticated-orcid":false,"given":"Apostolia M","family":"Tsimberidou","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedrik M","family":"Britten","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies GmbH, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"2025100311020062000_12.7.e008668.1","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.5223"},{"key":"2025100311020062000_12.7.e008668.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2116863"},{"key":"2025100311020062000_12.7.e008668.3","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.338"},{"key":"2025100311020062000_12.7.e008668.4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jha2.356","article-title":"CAR T cell therapy in solid tumors: a review of current clinical trials","volume":"3","author":"Patel","year":"2022","journal-title":"EJHaem"},{"key":"2025100311020062000_12.7.e008668.5","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01115-0","article-title":"T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors","volume":"14","author":"Tsimberidou","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025100311020062000_12.7.e008668.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116"},{"key":"2025100311020062000_12.7.e008668.7","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or Ipilimumab in advanced Melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100311020062000_12.7.e008668.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y"},{"key":"2025100311020062000_12.7.e008668.9","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0269"},{"key":"2025100311020062000_12.7.e008668.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119662"},{"key":"2025100311020062000_12.7.e008668.11","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0040"},{"key":"2025100311020062000_12.7.e008668.12","first-page":"2281","article-title":"Expression of MAGE-A cancer\/Testis antigens in Esophageal squamous cell Carcinomas","volume":"26","author":"Haier","year":"2006","journal-title":"Anticancer Res"},{"key":"2025100311020062000_12.7.e008668.13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601600"},{"key":"2025100311020062000_12.7.e008668.14","doi-asserted-by":"publisher","DOI":"10.1002\/hed.10223"},{"key":"2025100311020062000_12.7.e008668.15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13045-019-0793-7","article-title":"MAGE-A1 in lung adenocarcinoma as a promising target of Chimeric antigen receptor T cells","volume":"12","author":"Mao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2025100311020062000_12.7.e008668.16","first-page":"4072","article-title":"A MAGE-A1 HLA-A A*0201 EPITOPE identified by mass spectrometry","volume":"61","author":"Pascolo","year":"2001","journal-title":"Cancer Res"},{"key":"2025100311020062000_12.7.e008668.17","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2025100311020062000_12.7.e008668.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2025100311020062000_12.7.e008668.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2025100311020062000_12.7.e008668.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025100311020062000_12.7.e008668.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2025100311020062000_12.7.e008668.22","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201700284","article-title":"Translating immunopeptidomics to immunotherapy-decision-making for patient and personalized target selection","volume":"18","author":"Fritsche","year":"2018","journal-title":"Proteomics"},{"key":"2025100311020062000_12.7.e008668.23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.10.4974"},{"key":"2025100311020062000_12.7.e008668.24","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3358"},{"key":"2025100311020062000_12.7.e008668.25","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1110\/ps.8.11.2418","article-title":"Production of soluble Alphabeta T-cell receptor Heterodimers suitable for biophysical analysis of ligand binding","volume":"8","author":"Willcoj","year":"1999","journal-title":"Protein Science"},{"key":"2025100311020062000_12.7.e008668.26","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1038\/s41598-021-83858-x","article-title":"Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in Paraffin tumor tissues","volume":"11","author":"Parra","year":"2021","journal-title":"Sci Rep"},{"key":"2025100311020062000_12.7.e008668.27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020255","article-title":"Procedural requirements and recommendations for multiplex Immunofluorescence Tyramide signal amplification assays to support translational oncology studies","volume":"12","author":"Parra","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100311020062000_12.7.e008668.28","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1673129","article-title":"The promise of adoptive cellular immunotherapies in hepatocellular carcinoma","volume":"9","author":"Hendrickson","year":"2020","journal-title":"Oncoimmunology"},{"key":"2025100311020062000_12.7.e008668.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-005-1615-y"},{"key":"2025100311020062000_12.7.e008668.30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0168-8278(03)00484-7","article-title":"Ex vivo characterization of tumor-derived Melanoma antigen encoding gene-specific CD8+Cells in patients with hepatocellular carcinoma","volume":"40","author":"Zerbini","year":"2004","journal-title":"J Hepatol"},{"key":"2025100311020062000_12.7.e008668.31","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22309"},{"key":"2025100311020062000_12.7.e008668.32","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3892\/or.2011.1566","article-title":"MAGE A1-A6 RT-PCR and MAGE A3 and P16 methylation analysis in induced Sputum from patients with lung cancer and non-malignant lung diseases","volume":"27","author":"Shin","year":"2012","journal-title":"Oncol Rep"},{"key":"2025100311020062000_12.7.e008668.33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003581","article-title":"Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer","volume":"10","author":"Blumenschein","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100311020062000_12.7.e008668.34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.818679","article-title":"Phase 1 clinical trial evaluating the safety and anti-tumor activity of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ head and neck, Melanoma, or urothelial tumors","volume":"12","author":"Hong","year":"2022","journal-title":"Front Oncol"},{"key":"2025100311020062000_12.7.e008668.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2708"},{"key":"2025100311020062000_12.7.e008668.36","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0762-2","article-title":"Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in Synovial sarcoma","volume":"7","author":"Ramachandran","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100311020062000_12.7.e008668.37","doi-asserted-by":"crossref","first-page":"11562","DOI":"10.1200\/JCO.2022.40.16_suppl.11562","article-title":"Identification of response stratification factors from pooled efficacy analyses of Afamitresgene Autoleucel (\u201cAfami-Cel\u201d [formerly ADP-A2M4]) in metastatic Synovial sarcoma and Myxoid\/round cell Liposarcoma phase 1 and phase 2 trials","volume":"40","author":"D\u2019Angelo","year":"2022","journal-title":"JCO"},{"key":"2025100311020062000_12.7.e008668.38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2020.38.15_suppl.102","article-title":"Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors","volume":"38","author":"Hong","year":"2020","journal-title":"JCO"},{"key":"2025100311020062000_12.7.e008668.39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1921964117"},{"key":"2025100311020062000_12.7.e008668.40","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242606"},{"key":"2025100311020062000_12.7.e008668.41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00244","article-title":"Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies","volume":"4","author":"Stone","year":"2013","journal-title":"Front Immunol"},{"key":"2025100311020062000_12.7.e008668.42","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1417"},{"key":"2025100311020062000_12.7.e008668.43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501222"},{"key":"2025100311020062000_12.7.e008668.44","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2022.100089","article-title":"MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic Melanoma: a phase I\/IIa clinical trial","volume":"15","author":"Rohaan","year":"2022","journal-title":"Immunooncol Technol"},{"key":"2025100311020062000_12.7.e008668.45","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2010.00904.x"},{"key":"2025100311020062000_12.7.e008668.46","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00234-5"},{"key":"2025100311020062000_12.7.e008668.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.08.036"},{"key":"2025100311020062000_12.7.e008668.48","doi-asserted-by":"publisher","DOI":"10.1038\/nature01076"},{"key":"2025100311020062000_12.7.e008668.49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402346"},{"key":"2025100311020062000_12.7.e008668.50","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02306-y","article-title":"Unleashing the immune response to NY-ESO-1 cancer Testis antigen as a potential target for cancer immunotherapy","volume":"18","author":"Raza","year":"2020","journal-title":"J Transl Med"},{"key":"2025100311020062000_12.7.e008668.51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.12.7308"},{"key":"2025100311020062000_12.7.e008668.52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2537"},{"key":"2025100311020062000_12.7.e008668.53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00947"},{"key":"2025100311020062000_12.7.e008668.54","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26840","article-title":"Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells","volume":"2","author":"Bossi","year":"2013","journal-title":"Oncoimmunology"},{"key":"2025100311020062000_12.7.e008668.55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1247"},{"key":"2025100311020062000_12.7.e008668.56","first-page":"S147","article-title":"Chimeric antigen receptor T cell therapies: a review of cellular kinetic-pharmacodynamic modeling approaches","volume":"60 Suppl 1","author":"Chaudhury","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2025100311020062000_12.7.e008668.57","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/psp4.12598","article-title":"Bench-to-bedside translation of Chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: a case study with anti-BCMA CAR-T","volume":"10","author":"Singh","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025100311020062000_12.7.e008668.58","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000525"},{"key":"2025100311020062000_12.7.e008668.59","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3910"},{"key":"2025100311020062000_12.7.e008668.60","doi-asserted-by":"crossref","unstructured":"Van Tine B , Hong D , Johnson M , et al . Durable responses in patients with Synovial sarcoma in the phase 1 trial of ADP-A2M4 (MAGE-A4). 2020. doi:10.1093\/annonc\/mdz283.003","DOI":"10.1093\/annonc\/mdz283.003"},{"key":"2025100311020062000_12.7.e008668.61","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"2025100311020062000_12.7.e008668.62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1812800116"},{"key":"2025100311020062000_12.7.e008668.63","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.128"},{"key":"2025100311020062000_12.7.e008668.64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-828343"},{"key":"2025100311020062000_12.7.e008668.65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388"},{"key":"2025100311020062000_12.7.e008668.66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237646","article-title":"Tumor-infiltrating CD62L+PD-1-CD8 T cells retain proliferative potential via BCL6 expression and replenish effector T cells within the tumor","volume":"15","author":"Gong","year":"2020","journal-title":"PLoS One"},{"key":"2025100311020062000_12.7.e008668.67","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2017.25"},{"key":"2025100311020062000_12.7.e008668.68","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0928-8"},{"key":"2025100311020062000_12.7.e008668.69","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-34814-8_11"},{"key":"2025100311020062000_12.7.e008668.70","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.V75.7.1531.1531","article-title":"CD28 ligation in T-cell activation: evidence for two signal transduction pathways","volume":"75","author":"Ledbetter","year":"1990","journal-title":"Blood"},{"key":"2025100311020062000_12.7.e008668.71","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000158855.92792.7a"},{"key":"2025100311020062000_12.7.e008668.72","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CJI.0b013e318209c94c","article-title":"Establishment and large-scale expansion of minimally cultured \"young\" tumor infiltrating lymphocytes for adoptive transfer therapy","volume":"34","author":"Itzhaki","year":"2011","journal-title":"J Immunother"},{"key":"2025100311020062000_12.7.e008668.73","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb9847"},{"key":"2025100311020062000_12.7.e008668.74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1433"},{"key":"2025100311020062000_12.7.e008668.75","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4015"},{"key":"2025100311020062000_12.7.e008668.76","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-021-00175-8","article-title":"Industrializing engineered autologous T cells as medicines for solid tumours","volume":"20","author":"Britten","year":"2021","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-008668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:02:14Z","timestamp":1759514534000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-008668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":76,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,22]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/jitc-2023-008668"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-008668","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}